Ki-67的表达与原发性乳腺癌CEF新辅助化疗疗效的相关性研究

Correlation of expression of Ki-67 and outcome of CEF neoadjuvant chemotherapy in breast cancer

目的:探讨经过CEF新辅助化疗的乳腺癌患者组织中Ki-67表达的变化及与其病理疗效的相关性。方法:选取新疆医科大学附属肿瘤医院2004年1月至2009年10月间经CEF方案新辅助化疗的47例乳腺癌患者细针穿刺活检及手术切除的癌组织标本,用免疫组织化学法检测癌组织中的Ki-67的表达情况。结果:CEF新辅助化疗方案的病理疗效与乳腺癌的临床病理特征,包括年龄、肿瘤大小、组织分级、组织类型、ER/PR的表达情况没有关联(P>0.05);Ki-67在CEF新辅助化疗后,有效组与无效组的阳性率分别为77.8%,44.8%,差异存在统计学意义(P<0.05),化疗后Ki-67的表达与化疗前的表达存在差异(31.70%vs 56.1%,P<0.05)。结论:CEF新辅助化疗方案的病理疗效不受乳腺癌临床病理特征的影响;Ki-67的高表达预示着对CEF方案的化疗有较高的敏感性。

Objective：To investigate the change of Ki-67 in breast cancer tissue through CEF neoadjuvant chemotherapy and association with pathologic respone.Methods： Breast cancer specimens were collected from 47 patients who underwent operation and FNB in the Affiliated Tumor Hospital of Xinjiang Medical University during 2004 and 2009.The expression of Ki-67 in the breast cancer tissue was determined by immunohistochemical staining.Results： There was no correlation in tumor size,histologic grade,patient＇s age,cancer type,expression of ER/PR with pathologic response of CEF neoadjuvant chemotherapy（P0.05）;The efficiency for responser and noresponser was respectively 77.8% and 44.8% in postchemotherpy and there was stastical difference（P0.05）;There was stastical difference in expression of Ki-67 between prechemotherpy and postchemotherpy（56.09% vs 31.70%,P0.05）.Conclusion： Pathologic response of CEF neoadjuvant chemotherapy was not influenced by clinical pathological features;The high expression of Ki-67 implied the better sensitivity to CEF neoadjuvant chemotherapy.